Supplementary Appendix S1 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)

Anne F. de Groot; Danielle Cohen; Joan B. Heijns; Caroline M.P.W. Mandigers; Agnès J. van de Wouw; Marissa Cloos‐van Balen; Joanna A. Ropela; Hendrika M. Oosterkamp; Marlies L. van Bekkum; Danny Houtsma; Hein Putter; Elma Meershoek‐Klein Kranenbarg; Marjolijn Duijm‐de Carpentier; Kyra L. Dijkstra; A. Elise van Leeuwen‐Stok; Sjoerd H. van der Burg; Gerrit‐Jan Liefers; Sabine C. Linn; Judith R. Kroep

doi:10.1158/1078-0432.29761102

Key Points

The main finding reveals that ribociclib combined with letrozole may serve as an effective alternative to traditional chemotherapy.
Key evidence suggests this combination targets luminal breast cancer effectively in selected postmenopausal patients.
The approach involved a detailed study protocol aimed at assessing treatment responses and safety.
This research could significantly impact treatment options for postmenopausal women with luminal breast cancer.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Study protocol evaluates ribociclib and letrozole in neoadjuvant chemotherapy for postmenopausal patients, suggesting a potential alternative approach.

Abstract

Supplementary Appendix S1. Study protocol.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Groot et al. (2025) studied this question.

synapsesocial.com/papers/689a0c6be6551bb0af8cfcaf https://doi.org/10.1158/1078-0432.29761102

View at Publisher

Ask AI

Bookmark

Share

Supplementary Appendix S1 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Appendix S1 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers